Disc Medicine IRON Significant Segment Expense Category — Commercial Expense

Similar metrics at other companies

CRNXReportable Segment — Commercial Selling, General And Administrative Personnel Expenses

$20.04M+65.7%

MIRMReportable Segment — Commercialization and Medical Affairs expenses (excluding stock-based compensation)

$44.22M+23.6%

CDWCommercial — Other segment expense items

$443.4M+14.0%

PSNCritical Infrastructure — Significant Segment Expense

$47.46M+2.9%

HURNCommercial: — Selling, general and administrative expenses

$6.29M+9.3%

RYTMSingle reportable segment — Commercial & medical affairs

$20.26M+52.9%

Questions, answered.

What is Disc Medicine's significant segment expense category — commercial expense?

Disc Medicine (IRON) reported significant segment expense category — commercial expense of -$8.43M in Q1 2026.

How has Disc Medicine's significant segment expense category — commercial expense changed year-over-year?

Disc Medicine's significant segment expense category — commercial expense decreased by 339.0% year-over-year, from -$1.92M to -$8.43M.

What is the long-term trend for Disc Medicine's significant segment expense category — commercial expense?

Over 2 years (2023 to 2025), Disc Medicine's significant segment expense category — commercial expense has grown at a 284.4% compound annual growth rate (CAGR), from -$1.01M to -$14.88M.

What does significant segment expense category — commercial expense mean?

This metric represents the costs incurred by the company to support the market launch, promotion, and distribution of its therapeutic candidates. It reflects the investment in commercial infrastructure and activities necessary to transition from clinical development to product commercialization. Monitoring this expense helps investors assess the company's readiness and financial commitment to bringing its hematologic therapies to market.